C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 38/16 (2006.01) A61K 38/20 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01) C07H 21/00 (2006.01) C07K 14/47 (2006.01) C07K 16/18 (2006.01) C12Q 1/02 (2006.01) G01N 33/53 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2133759
A soluble immunosuppressive factor present in serum derived from tumor-bearing mammals, is associated with changes in TCR protein subunit levels, T lymphocyte signal transduction pathway proteins. These changes provide a method of determining the level of immunosuppression in a mammal by determining the level of expression of at least one selected TCR subunit protein, a protein in the T lymphocyte signal transduction pathway, or of the NF-KB/rel family and comparing the level and pattern to chat found in non-immunosuppressed individuals: The method is useful to identify patients having T lymphocytes capable of acti- vation for immunotherapy and for identifying agents which cause or reverse immunosuppression. An isolated immunosuppres- sive factor associated with the level of expression of the proteins is useful for suppressing the immune response, for example, in organ transplantation.
Ghosh Paritosh
Loeffler Cynthia T.
Longo Dan L.
Mizoguchi Hiromoto
O'shea John J.
Fetherstonhaugh & Co.
Ghosh Paritosh
Loeffler Cynthia T.
Longo Dan L.
Mizoguchi Hiromoto
LandOfFree
Evaluation and treatment of patients with progressive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Evaluation and treatment of patients with progressive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Evaluation and treatment of patients with progressive... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1848369